Does olaparib (Olaparib, Lipadrox) have any effect on platinum-resistant ovarian cancer?

For patients with platinum-resistant ovarian cancer, the therapeutic effect of Lynparza (Olaparib, Lipadro) is a matter of great concern. Platinum resistance means that traditional platinum-based chemotherapy regimens are ineffective for patients, so it is particularly important to explore new treatment drugs and methods.

Olaparib is a PARP inhibitor. By inhibiting the activity of PARP enzyme, it interferes with the DNA repair mechanism of tumor cells, thereby achieving the effect of killing cancer cells. This unique mechanism of action makes olaparib potentially advantageous in the treatment of platinum-resistant ovarian cancer.

Although olaparib was originally approved for the maintenance treatment of platinum-sensitive recurrent ovarian cancer, its efficacy in platinum-resistant ovarian cancer has also received attention. Some studies have shown that olaparib can also show certain therapeutic effects in some platinum-resistant patients.

In relevant clinical studies, although the efficacy of olaparib in platinum-resistant patients is not as significant as that in platinum-sensitive patients, there are still some patients who can benefit from olaparib treatment. These patients often experience positive responses such as tumor marker decline, disease stabilization, or remission.

It should be noted that olaparib is not effective in all patients with platinum resistance. Therefore, a comprehensive evaluation, including genetic testing, tumor marker testing, etc., should be conducted before use to determine whether the patient is suitable for olaparib treatment. At the same time, Lynparza may also cause some side effects, such as anemia, nausea, etc., which need to be handled under the guidance of a doctor.